Source https://www.fightaging.org/archives/2025/12/a-glp-1-receptor-agonist-fails-to-slow-alzheimers-disease-in-a-phase-3-trial/
On the one hand there is a modest amount of evidence for GLP-1 receptor agonist drugs to produce beneficial effects on an aged metabolism that are unconnected to weight loss. On the other hand, when Big Pharma has a very successful drug, it will attempt to use that drug for every condition it can that is associated with a sizable market, whether or not the expected effects are marginal. So it isn’t necessarily indicative of support for these non-weight-loss mechanisms that leads the clinical trial of a weight loss drug for patients with Alzheimer’s disease. Cynically, it is that Alzheimer’s is an enormous market.
The <a href="https://www.fightaging.org/archives/2014/11/the-ridiculous-cost-of-medical-research-regula…
Source https://www.fightaging.org/archives/2025/12/a-glp-1-receptor-agonist-fails-to-slow-alzheimers-disease-in-a-phase-3-trial/
On the one hand there is a modest amount of evidence for GLP-1 receptor agonist drugs to produce beneficial effects on an aged metabolism that are unconnected to weight loss. On the other hand, when Big Pharma has a very successful drug, it will attempt to use that drug for every condition it can that is associated with a sizable market, whether or not the expected effects are marginal. So it isn’t necessarily indicative of support for these non-weight-loss mechanisms that leads the clinical trial of a weight loss drug for patients with Alzheimer’s disease. Cynically, it is that Alzheimer’s is an enormous market.
The <a href="https://www.fightaging.org/archives/2014/11/the-ridiculous-cost-of-medical-research-regula…
What Do You Think?
comments